Wyeth's Conbriza gets EU recommendation for osteoporosis
This article was originally published in Scrip
Executive Summary
The EU's CHMP has adopted a positive opinion of Wyeth's selective oestrogen receptor blocker (SERM) Conbriza (bazedoxifene, 20mg film-coated tablets) for the treatment of osteoporosis in postmenopausal women at increased risk of bone fracture.